Lymphocyte subsets in ITP patients at diagnosis and controls
| Variable . | ITP patients (n = 27) . | Controls (n = 28) . | P . |
|---|---|---|---|
| Age, y | 54.1 ± 22.5 | 54.6 ± 21.4 | .9 |
| Female/male, % | 59.3/40.7 | 67.9/32.1 | .58 |
| Hemoglobin, g/L | 135 ± 19 | 135 ± 14 | .88 |
| Platelets, ×109/L | 21.0 ± 12.5 | 245.2 ± 89.7 | < .0001 |
| Leucocytes, ×109/L | 7.7 ± 3.7 | 6.8 ± 2.1 | .8 |
| Lymphocytes, ×109/L | 1.9 ± 0.7 | 2.1 ± 0.8 | .35 |
| CD3+, % | 75.1 ± 8.6 | 72.8 ± 8.6 | .37 |
| CD3+, ×109/L | 1.4 ± 0.11 | 1.5 ± 0.13 | .42 |
| CD4+, % | 49.9 ± 9.4 | 48.7 ± 8.5 | .48 |
| CD4+, ×109/L | 0.93 ± 0.44 | 1.03 ± 0.48 | .42 |
| CD8+, % | 26.1 ± 11.3 | 21.6 ± 7.9 | .16 |
| CD8+, ×109/L | 0.47 ± 0.26 | 0.46 ± 0.25 | .89 |
| CD19+, % | 10.6 ± 5.7 | 10.7 ± 4.3 | .86 |
| CD19+, ×109/L | 0.21 ± 0.16 | 0.22 ± 0.13 | .44 |
| κ/λ | 1.7 ± 0.6 | 1.6 ± 0.4 | .22 |
| CD16+CD56+, % | 10.5 ± 5.9 | 14.7 ± 7.8 | .054 |
| CD16+CD56+, ×109/L | 0.19 ± 0.14 | 0.29 ± 0.15 | .05 |
| Variable . | ITP patients (n = 27) . | Controls (n = 28) . | P . |
|---|---|---|---|
| Age, y | 54.1 ± 22.5 | 54.6 ± 21.4 | .9 |
| Female/male, % | 59.3/40.7 | 67.9/32.1 | .58 |
| Hemoglobin, g/L | 135 ± 19 | 135 ± 14 | .88 |
| Platelets, ×109/L | 21.0 ± 12.5 | 245.2 ± 89.7 | < .0001 |
| Leucocytes, ×109/L | 7.7 ± 3.7 | 6.8 ± 2.1 | .8 |
| Lymphocytes, ×109/L | 1.9 ± 0.7 | 2.1 ± 0.8 | .35 |
| CD3+, % | 75.1 ± 8.6 | 72.8 ± 8.6 | .37 |
| CD3+, ×109/L | 1.4 ± 0.11 | 1.5 ± 0.13 | .42 |
| CD4+, % | 49.9 ± 9.4 | 48.7 ± 8.5 | .48 |
| CD4+, ×109/L | 0.93 ± 0.44 | 1.03 ± 0.48 | .42 |
| CD8+, % | 26.1 ± 11.3 | 21.6 ± 7.9 | .16 |
| CD8+, ×109/L | 0.47 ± 0.26 | 0.46 ± 0.25 | .89 |
| CD19+, % | 10.6 ± 5.7 | 10.7 ± 4.3 | .86 |
| CD19+, ×109/L | 0.21 ± 0.16 | 0.22 ± 0.13 | .44 |
| κ/λ | 1.7 ± 0.6 | 1.6 ± 0.4 | .22 |
| CD16+CD56+, % | 10.5 ± 5.9 | 14.7 ± 7.8 | .054 |
| CD16+CD56+, ×109/L | 0.19 ± 0.14 | 0.29 ± 0.15 | .05 |
Results are expressed as means ± SD except for the sex ratio.